News|Podcasts|January 27, 2023
Episode 81: Widening the Therapeutic Window in Parkinson Disease
Author(s)Matt Hoffman
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]
Advertisement
Episode 81 of the NeurologyLive® Mind Moments ® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 81, "Widening the Therapeutic Window in Parkinson Disease," features an exclusive interview with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.
This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845 Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy
EPISODE BREAKDOWN
- 1:20 – Lingering unmet needs in Parkinson disease management
- 3:10 – The advances in identifying therapeutic targets in PD
- 4:25 – Bridging the gap to more effective long-term treatment
- 6:00 – Overview of IPX203 and its potential to treat PD
- 7:45 – Neurology News Minute
- 10:15 – Possible advantages of IPX203
- 13:25 – Safety profile of IPX203 in clinical development
- 15:50 – The importance of addressing dose-wearing off
- 16:40 – Closing thoughts
Hoping to listen on your favorite podcast app? See below:
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
2025 Women in Neurology Conference: Educating, Mentoring, and Networking
5